Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 3 trial found that adding the HDAC inhibitor HBI-8000 to nivolumab significantly improved progression-free survival in unresectable melanoma — by over 4 months overall, and a striking 13 months in patients with normal LDH levels. Researchers are calling it a potential standard-of-care option, though the combo came with notably higher rates of serious side effects.
A phase 3 randomized trial presented at ESMO 2026 in Madrid found that combining the investigational HDAC inhibitor HBI-8000 with nivolumab significantly improved progression-free survival (PFS) in patients with unresectable advanced melanoma. The trial enrolled 404 patients across 123 sites in 15 countries, all of whom were checkpoint inhibitor-naïve.
The combination delivered a meaningful edge over nivolumab alone, with the benefit amplified in patients who had normal lactate dehydrogenase (LDH) levels at baseline — a majority of the study population. Lead investigator Dr. Nikhil Khushalani of Moffitt Cancer Center suggested the regimen "can certainly be considered a standard-of-care option," citing the added convenience of oral dosing. ESMO discussant Dr. Olivier Michielin noted the results compare favorably to landmark trials like CheckMate 067 and RELATIVITY-047, though he urged caution pending mature overall survival data.
By the Numbers:
Why it matters: This trial positions HBI-8000 as a promising first-line addition for advanced melanoma, particularly for patients with normal LDH — but the significantly higher toxicity burden means clinicians will need to weigh benefits carefully until full overall survival data matures.
